Biopharma is the most profitable health care segment for private equity investors, but the opportunities for PE firms within biopharma, always scarce, may be dwindling further.
Trends that made the industry ripe for private equity (PE) investment are shifting – internal cost-cutting and restructuring initiatives are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?